AIV Logo AIV Assistant

Loading...

 Logo BiomX Inc. - PHGE Open BiomX Inc. in new tab

0.54
P/E
0.02
EPS
-0.02
P/B
30.53
ROE
-0.80
Beta
1.46

0.5378

0.538

Daily: -1.63%
Key Metrics

Earnings date: Nov. 13, 2025

P/E: 0.02

EPS: -0.02

Book Value: 0.02

Price to Book: 30.53

Debt/Equity: 48.94

% Insiders: 0.188%

Estimates

Forward P/E: -0.49

 Logo About BiomX Inc. - (PHGE)

Country: Israel

Sector: Health Care

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion